Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617

被引：0
|
作者：
Ferdinandus, J. [1 ]
Eppard, E. [1 ]
Kuerpig, S. [1 ]
Gaertner, F. [1 ]
Fimmers, R. [1 ]
Yordanova, A. [1 ]
Hauser, S. [1 ]
Essler, M. [1 ]
Feldmann, G. [1 ]
Ahmadzadehfar, H. [1 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPW12
引用
收藏
页码：S212 / S213
页数：2
相关论文
共 50 条
  • [41] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [42] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [43] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Heinzel, Alexander
    Boghos, Dima
    Mottaghy, Felix M.
    Gaertner, Florian
    Essler, Markus
    von Mallek, Dirk
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1054 - 1062
  • [44] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Fadi Khreish
    Niklas Kochems
    Florian Rosar
    Amir Sabet
    Martin Ries
    Stephan Maus
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112
  • [45] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Khreish, Fadi
    Kochems, Niklas
    Rosar, Florian
    Sabet, Amir
    Ries, Martin
    Maus, Stephan
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 103 - 112
  • [46] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [47] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [48] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Alexander Heinzel
    Dima Boghos
    Felix M. Mottaghy
    Florian Gaertner
    Markus Essler
    Dirk von Mallek
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1054 - 1062
  • [49] Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
    Reyhaneh Manafi-Farid
    Sara Harsini
    Bahare Saidi
    Hojat Ahmadzadehfar
    Ken Herrmann
    Alberto Briganti
    Jochen Walz
    Mohsen Beheshti
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 4028 - 4041
  • [50] Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use
    Ahmadzadehfar, Hojjat
    Essler, Markus
    Schaefers, Michael
    Rahbar, Kambiz
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 835
12345